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ABSTRACT: The compromise of quality of life in Hun-
tington’s disease is a major issue, both for individuals with
the disease as well as for their caregivers. The International
Parkinson and Movement Disorder Society commissioned
a review of the use and clinimetric validation status of mea-
sures used in Huntington’s disease to assess aspects
related with quality of life and to make recommendations
on their use following standardized criteria. We included
both patient-centered measures (patient health-related
quality-of-life measures) and caregiver-centered measures
(caregiver quality-of-life measures). After conducting a sys-
tematic literature search, we included 12 measures of
patient health-related quality of life and 2 measures of care-
giver quality of life. Regarding patient-centered measures,
the Medical Outcomes Study 36-Item Short-Form Health
Survey is “recommended” as a generic assessment of
health-related quality of life in patients with Huntington’s
disease. The 12-Item Short Form Health Survey, the Sick-
ness Impact Profile, the 12-item World Health Organization
Disability Assessment Schedule, and the Huntington’s Dis-
ease Health-Related Quality of Life questionnaire are
“suggested.” No caregiver-centered quality-of-life measure
obtained a “recommended” status. The Alzheimer’s Carer’s
Quality of Life Inventory and the Huntington’s Disease Qual-
ity of Life Battery for Carers are “suggested.” Recognizing
that the assessment of patient health-related quality of life
can be challenging in Huntington’s disease, as patients
may lack insight and there is insufficient clinimetric testing
of these scales, the committee concluded that further
validation of currently available health-related quality-of-
life measures should be undertaken, namely, those Hun-
tington’s disease–specific health-related quality-of-life
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Huntington’s disease (HD) is a complex neurodegener-
ative disorder in which motor, cognitive, and behavioral
manifestations have a significant impact on the health-
related quality of life (HRQoL) of patients. The concept
of HRQoL has been developed to express the aspects of
overall quality of life (QoL) that can be clearly shown to
be related to health, physical or mental.1 The World
Health Organization (WHO) defines health as “a state
of complete physical, mental, and social well-being not
merely the absence of disease.”2 The WHO lists the fol-
lowing functioning domains as being part of HRQoL:
physical, social, relational, and emotional well-being.1
Although the term “QoL” is often used interchangeably
with the term “HRQoL,” QoL is a much broader multi-
dimensional concept. The WHO defines QoL as “the
individuals’ perception of their position in life in the con-
text of the culture and value systems in which they live
and in relation to their goals, expectations, standards
and concerns.”1 Another important concept that is often
used in QoL literature is health status (HS). HS is defined
as the perceived health in descriptive terms of physical
and mental symptoms, disability, and social dysfunction
related to the health condition.3 It is different from
HRQoL in that it lacks judgments and reactions.3 As
stated in a similar review for HRQoL measures used in
Parkinson’s disease, it is reasonable to consider HS as a
relevant factor for HRQoL, which is a component of
QoL in general.4
HRQoL is an important patient-reported outcome
that constitutes a core assessment of the efficacy of
clinical interventions in HD, as these interventions ide-
ally seek to not only improve patients’ symptoms but
also ultimately to improve patient QoL. It is therefore
important that valid and reliable measures are avail-
able that can be used in HD. In addition to measures
centered on patients (patient-centered HRQoL mea-
sures), we also included measures centered on care-
givers and their own QoL (caregiver-centered QoL
measures), recognizing that HD impacts the “global”
QoL of caregivers and a potential change in QoL is
not necessarily related to health and may include other
aspects of life.5,6
Methods
Organization and Critique Process
The Committee on Rating Scales Development of the
MDS appointed a team of 10 members (subcommittee)
to review clinical measures used in HD to assess
HRQoL measures; these members included specialists
in HD and an expert in scale development and clinimet-
rics (A.M.D.). Two subcommittee members evaluated
each measure. If a subcommittee member was involved
in the development of a measure, he/she was not
involved in its review. Data were extracted into a pro-
forma form provided by the MDS and adapted for the
purpose of the current review. The assessment of the
measure included the description of the measure, its
availability, context of use, and reported clinimetric
properties in patients with HD. All subcommittee mem-
bers jointly assessed the completed reviews of the mea-
sures. Any unresolved issues and limitations of the
critiqued measures were identified for discussion and
reporting. The final recommendations were based on
consensus among the subcommittee members and the
liaison member of the Committee on Rating Scales
Development of the MDS (E.C.).
Selection of Measures
The methodology for this review was modeled on a
previously used methodology.7 A literature search was
performed using Medline on PubMed, Web of Science,
EMBASE, and Psychinfo. The keywords used in the
search included the following: “Huntington*” OR
“Westphal variant” OR “juvenile Huntington,*” and
the terms “scale” OR “questionnaire” OR “index” OR
“measure” as well as the keywords “Quality of life,”
“QoL,” “health-related quality of life,” “HRQoL,” and
“health status.” For each identified clinical measure, a
search was conducted for the terms “Huntington’s dis-
ease” or “Huntington disease” or “Huntington*” and
the name of the measure. Manuscripts published before
October 17, 2016, were retrieved using the above
search strategy and thoroughly screened by the chair of
the subcommittee (T.A.M.) to ascertain which measure
had been used in each study.
Inclusion/Exclusion for Review
Measures used at least once in HD populations
(patients at risk, presymptomatic gene carriers, and
symptomatic HD patients) were included. Measures
were excluded from review if they were not available
in English, were only mentioned in reviews but not
used in an original study, were created for a specific
study without any information about their structure or
use, or if the full paper was not available (eg, abstract
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format only). In terms of construct of measures, the
subcommittee decided to include all measures pro-
posed by developers to capture HRQoL, QoL, or HS
that have been used in HD studies.
Criteria for Rating
We followed the Classification System for Scale Rec-
ommendation used by the MDS that uses the follow-
ing 3 criteria: (1) use in HD populations, (2) use in
HD by groups other than the original developers and
data on its use are available, (3) the available clinimet-
ric/psychometric data in HD support the goals of mea-
surement of severity (eg, evaluation of reliability,
construct validity, and score discrimination across
levels of symptom severity). Specific to this review,
although HRQoL is not a symptom per se, it reflects
the multidimensional construct of the impact of a dis-
ease/condition on QoL. The ability to differentiate
across different levels of severity still stands as funda-
mental for a valid assessment of HRQoL (or caregiver
QoL) in observational studies or clinical trials (for fur-
ther details, see Table 1.)
Results
Identified Measures and Their Use
in Clinical Research
A total of 21 clinical measures that have been used
in HD research studies were identified. Two of these
measures were excluded after abstract review because
of inadequacy of the measure construct (see Supple-
mentary Material). The remaining 19 clinical measures
were included for an in-depth review. Three measures
were excluded because (1) their sole use in HD was in
case series without any clinimetric data available (the
Manchester Assessment of Quality of Life, the Fatigue
Impact scale), (2) it was created solely for a single
study (a nonstandardized QoL question). We grouped
the 16 remaining measures into patient-centered
HRQoL measures (n514) and caregiver-centered
QoL measures (n52) (see Table 2).
For patient-centered HRQoL measures, only The
Medical Outcomes Study 36-Item Short-Form Health
Survey was (SF-36) received a classification of
“recommended” as a generic assessment of health sta-
tus in manifest HD (severity). The 12-Item Short Form
Health Survey (SF-12), the Sickness Impact Profile
(SIP), the Huntington’s Disease Health-Related Qual-
ity of Life Questionnaire (HDQoL), and the 12-item
World Health Organization Disability Assessment
Schedule (WHODAS 2.0) were classified as “sug-
gested” (see table 3 for clinimetric details of recom-
mended and suggested measures, and the
Supplementary Material for reviews of all assessments
classified as “suggested with caveats” or “listed”).
For caregiver-centered QoL measures, no measure
was “recommended” for any of the purposes consid-
ered in this review. The Alzheimer’s Carer’s Quality
of Life Inventory (ACQLI) and the Huntington’s Dis-
ease Quality of Life Battery for Carers (HD-QoL-C)
were classified as “suggested” (see the Supplementary
Material for overviews of all assessments classified as
“suggested with caveats” or “listed”).
Patient-Centered HRQoL Rating Scales
Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36). The SF-36 is an easy-to-administer
self-reported set of generic measures of patient health
status developed by the RAND Corporation as part of
the Medical Outcomes Study. The SF-36 assesses
8 functional dimensions–physical functioning, physical
role limitations, mental health, emotional role limita-
tions, social functioning, energy/vitality, pain, and
general health perceptions—that can be summarized
into 2 scores (physical and mental) and a global utility
index.8 The SF-36 has been widely used in HD,9-12
and the vast majority of the data were collected using
version 1 of the SF-36. The most current SF-36 ver-
sion 2 has less ambiguous wording, improved layout,
enhanced response choices for some items, and inc-
reased cross-cultural validity.
Internal consistency has been shown for the SF-36
subscales and domain and component scores (Cron-
bach’s a 0.80).9-12 The test-retest reliability coeffi-
cients, as measured by intraclass coefficient (ICC),
have been reported to be >0.70 for all domains, apart
from the “emotional role” domain (ICC5 0.63). The
mental health summary score has been shown to cor-
relate only with the Beck Depression Inventory (BDI),
TABLE 1. Classification system for scale recommendation
Category Criteria
“Recommended” (1) Scale has been used in HD populations.
(2) Use in HD by groups other than the
original developers and data on its use
were available.a
(3) The available clinimetric/psychometric
data in HD support the goals of
screening (eg, evaluation of sensitivity/
specificity, score cut-off points, and
reliability) or measurement of severity
(eg, evaluation of reliability, construct
validity, and score discrimination across
levels of symptom severity).
“Suggested” (1) Scale has been used in HD populations.
(2) Only 1 other criteria (2) or (3) from the
above recommended category applies.
“Listed” (1) Scale has been applied to HD
populations, but no further criterion met.
HD, Huntington’s Disease.
aFor rating scales not originally developed for use in HD, criterion 2 was
fulfilled if used in at least 1 group in HD that reported any kind of clinimet-
ric/psychometric data in HD.
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TABLE 2. Summary of all included scales in HD
Scale/Questionnaire
Developed














Medical Outcomes Study 36-
Item Short-Form Health
Survey (SF-36)
No Yes Yes Yes Recommended as a
generic assessment
of health status in
manifest HD
(severity)
Most of the clinimetric
data in HD were
generated using
older version 1
Medical Outcomes Study 12-
Item Short-Form Health
Survey (SF-12)
No Yes Yes No Suggested as a
generic assessment
of health status in
manifest HD
(severity)


























No Yes Yes No Suggested with
caveats
Used in a single study
Neuro-Quality of Life
(Neuro-QoL)
No Yes Yes No Suggested with
caveats
Used in a single study
PROMIS Global Health
(PROMIS)
No Yes Yes No Suggested with
caveats
Used in a single study
Huntington Disease Health-
Related Quality of Life
(HDQLIFE)
Yes Yes No No Listed
WHO-Quality of Life-BREF
(WHOQOL-BREF)
No Yes No No Listed
Quality of Life Index (QoL
Index)
No Yes No No Listed
Huntington Quality of Life
Instrument (H-QoL-I)
Yes Yes No No Listed
HD-PRO-TRIAD Yes Yes No No Listed
Caregiver-Centered Assessments
The Alzheimer’s Carer’s
Quality of Life Inventory
(AQLI)
No Yes Yes No Suggested for
assessing quality of
life for HD care-
givers (severity)
Huntington’s Disease Quality
of Life Battery for Carers
(HD-QoL-C)
Yes Yes Yes No Suggested for
assessing quality of
life for HD care-
givers (severity)
EQ-5D, EuroQol Five-Dimension Questionnaire; HD, Huntington’s Disease.
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whereas the physical health summary score of the SF-
36 correlates with the BDI and a patient’s self-rated
and clinician’s rating of patients’ level of functioning/
independence level, but no factor analysis has been
conducted for the SF-36 in this population. The SF-36
(total score, vitality score, and mental component
score) have been shown to be sensitive to change in
manifest HD clinical trials.9,11,13
Recommendation. The SF-36 is “recommended” as a
generic assessment of health status in manifest HD
(severity). The physical summary score seems to have
better construct validity in HD. It is not known if the
more recent SF-36 version 2 performs equally well in
HD as the SF-36 version 1.
Medical Outcomes Study 12-Item Short-Form Health
Survey (SF-12). The SF-12 is a 12-item shorter ver-
sion of the SF-36. It covers the same functional dimen-
sions as the SF-36 but includes fewer items and thus is
quicker to administer (2 minutes vs 8-12 minutes for
the SF-36).14 It has been used less extensively in HD
than the SF-36.8 It is currently being used in Enroll-
HD, but no data have been reported.15 Various
degrees of convergent validity have been reported
between the SF-12 physical and mental health
components, and the components of the HD-PRO-
Triad (SF-12 physical component, Pearson correla-
tions: motor, 20.79; cognition, 20.77; emotion/
behavioral dyscontrol, 20.47; total score, 20.76; SF-
12 mental component, cognition, 20.61; motor,
20.51; total score, 20.61), and emotion/behavioral
dyscontrol; Pearson correlation: 20.53, all P< .05).16
The SF-12 physical component, but not the mental
health component, has been shown to be sensitive to
change following multidisciplinary rehabilitation.17
Recommendation. The SF-12 is “suggested” as a
generic assessment of health status in manifest HD
(severity), as it lacks test-retest reliability data and
internal consistency data.
Sickness Impact Profile (136 Items). The SIP is a
generic measure of self-reported health status,18 con-
sisting of 136 items covering 12 categories grouped
into 2 subscales (physical and psychosocial). Scores
are presented as a percentage of maximal dysfunction
ranging from 0 to 100; a higher score indicates a
higher level of dysfunction. The SIP can take up to 30
minutes to complete. The SIP has been used in 2 stud-
ies in manifest HD,19,20 and a modified version using
only 3 of the 12 categories was used in trial for
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Data regarding Minimally Clinically Important Difference was not assessed in any of the scales. (1) - good performance, (1/2) contradictory data or very lim-
ited data, (2) poor performance. HD, Huntington’s disease; NR, not reported
aWe list the languages officially recognized as being used for scale translation, widespread5 scale translation has been recognized in more than 5 languages
bThe SF-36 was the only rating scale “recommended.” Remaining scales were “suggested.”
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cognition in HD.21 Internal consistency has been
reported to be high (Cronbach’s a> 0.80),19 as has
test-retest reliability (ICC>0.70) for scores of sub-
scales and all categories, aside from the “emotional
behavior” (ICC5 0.49) and “work” (ICC5 0.68) cat-
egories.19 The SIP total score has been shown to corre-
late with both the patient’s self-rated (Spearman
correlation, 20.69) and clinician’s rating (Spearman
correlation, 20.64) of patients’ level of functioning/
independence (all P< .01), with the BDI (Spearman
correlation, 0.47; P< .01), and with the Unified Hun-
tington’s Disease Rating Scale–Total Motor score
(UHDRS-TMS; Spearman correlation, 0.32; P< .05).
The Psychosocial subscale has been shown to correlate
with both the patient’s self-rated and the clinician’s
rating of patients’ level of functioning/independence,
whereas the Physical subscale has been shown to cor-
relate with both the BDI and the UHDRS-TMS in
addition to both the patient’s self-rated and the clini-
cian’s rating of patients’ level of functioning/indepen-
dence.19 In a head-to-head comparison with the SF-
36, the SIP was shown to have a worse clinimetric
performance with less robust construct validity and
test–retest reliability. In addition, motor symptoms
appeared to influence some strictly nonmotor dimen-
sions of the SIP.19
Recommendation. The SIP is “suggested” for assess-
ing health status in manifest HD (severity). There are
limited clinimetric data on its use in HD, and it
performs worse than the SF-36 in a head-to-head
comparison.
12-item World Health Organization Disability
Assessment Schedule (WHODAS) 2.0 . The WHO-
DAS 2.0 was developed by the WHO and is often
considered a generic function-related measure of
health status, and consequently it was decided by con-
sensus to include it in this review and not in the
review of measures for assessment of functional ability
in HD. The WHODAS 2.0 can be administered as
interviewer-, self-, and proxy-administered forms. The
WHODAS 2.0 12-item version, which is reviewed
here, takes 5 minutes to complete and covers the fol-
lowing 6 domains: cognition, mobility, self-care, get-
ting along, life activities, and participation. The
WHODAS 2.0 12-item has been used in three studies
including both premanifest and manifest HD.22-24
Internal consistency has been shown with a Cron-
bach’s a of 0.94 (95% CI, 0.93-0.94).22 Moderate
convergent validity has been reported between the
WHODAS 2.0 and other HRQoL assessments such as
the RAND-12 (Pearson correlations ranging from
20.76 to 20.41), and the EuroQol Five-Dimension
Questionnaire (Pearson correlations ranging
from520.65 and 20.49).22 The scores in the
WHODAS 2.0 differ significantly across the disease
spectrum from the premanifest stage to late HD.22 In
premanifest HD, cross-sectional differences between
low-, mid- and high-disease burden groups have been
reported.23 In premanifest HD, only the companion-
rated (proxy) version of the WHODAS 2.0 has been
shown to be sensitive to change over a period of 3
years.23
Recommendation. The WHODAS 2.0 12-item is
“suggested” for assessing health status in HD (sever-
ity), as it lacks important clinimetric development in
HD, namely, for test-retest reliability testing and
requires more robust construct validity.
HDQoL. The HDQoL is a patient-reported question-
naire that was specifically developed for use in HD to
assess HRQoL.25 The HDQoL covers the following 3
main domains: “primary physical and cognitive,”
“primary emotions and self,” and “primary serv-
ices.”25 It takes about 22 minutes to complete. The
HDQoL has been used in 1 study by authors26 other
than the group25,27 who originally developed it. The
internal consistency of each of the domains has been
shown to vary: “primary services” (Cronbach’s
a5 0.76), “primary emotions and self” (Cronbach’s
a5 0.89), and “primary physical and cognitive”
(Cronbach’s a50.96). Test-retest reliability has been
reported, but as this was evaluated with Cronbach’s a
it does not provide a true adequate measure of concor-
dance.25 Item ceiling effects range from 12.5% to
50%.25
Recommendation. The HDQoL is “suggested” for
assessment of HRQoL in HD (severity), as there are
limited clinimetric data, namely related with construct
validity and test-retest reliability.
Caregiver-Centered QoL Measures
The Alzheimer’s Carer’s Quality of Life Inventory
(ACQLI). The ACQLI was developed to assess care-
giver QoL in Alzheimer’s disease.28 It is a quick (<5
minutes) questionnaire that consists of 30 items to
which the caregiver answers true or not true; 1 point
is given for each true answer, giving a possible total
score of 30. The ACQLI has been used in a single HD
study, in a head-to-head comparison with the HD-
QoL-C. The ACQLI 29 showed excellent internal con-
sistency (Cronbach’s a50.95).29
Recommendation. The ACQLI is “suggested” for
assessing QoL for HD caregivers (severity), as its use
in HD is limited to a single study in HD and clinimet-
ric data in HD are limited to internal consistency.
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Huntington’s disease quality of life battery for carers
(HD-QoL C). The HD-QoL-C is a HD-specific, mul-
tidimensional measure for family or caregivers of
patients with HD. It is based on the domains and fac-
ets of the Comprehensive Quality of Life Scale for
Adults.30 Two versions are available: a long form that
consists of 34 items that incorporate measures on
“practical aspects of caregiving” (n5 9), “satisfaction
with life” (n58), and “feelings about living with
HD” (n517), and a short form that consists of 20
items (3 items on “satisfaction of life,” and 17 items
on “feelings about living with HD”).29 The HD-QoL-
C has been used in 4 studies in HD.9,29,31,32 Internal
consistency of the long form has been shown for the
domains “satisfaction with life” (Cronbach’s a5 0.91)
and “feelings about living with HD” (Cronbach’s
a5 0.84), but not for the domain “practical aspects
of caregiving” (Cronbach’s a50.62).29 For the short
form, internal consistency has been shown (“sat-
isfaction with life,” 0.92; total score, 0.88).29 A low
correlation has been reported between the HD-QoL-C
and the WHO Quality of Life Short Form,32 and the
Huntington Quality of Life Instrument (correlations
0.22 to 0.28; all P< .01).31
Recommendation. The HD-QoL-C is “suggested”
for assessing QoL for HD caregivers (severity). It war-
rants additional clinimetric development, namely in
terms of validity, reliability, and data reproducibility
by other groups.
Discussion
We report here the results of an in-depth review of 14
measures used in HD studies to evaluate patient-
centered HRQoL. The SF-36 is the only measure that
can be classified as “recommended” to measure patient’s
HRQoL in terms of severity. None of the HRQoL mea-
sures developed specifically for HD have undergone suf-
ficient clinimetric development to warrant a similar
classification level. There were no HRQoL measures rec-
ommended to measure change of severity over time.
Regarding patient-centered HRQoL measures, the sub-
committee identified the following topics that warrant
consideration when developing these types of measures:
1. The inherent subjective nature of self-reporting
HRQoL warrants a special comment as HD
patients often lack insight regarding the presence
or severity of their symptoms. Along the same
lines, the progressive cognitive impairment expe-
rienced by HD patients is likely to introduce
additional difficulties in ensuring the reliability of
patient-reported HRQoL in HD, namely, at later
stages. Proxy reporting was rarely included in the
measures reviewed here and could be further
assessed and considered as a strategy to mitigate
the previously mentioned limitations of patient-
reported outcomes in HD.
2. As HD is a rare disease, studies often require a
multicenter, multinational design that raises the
need for validation of HRQoL and QoL mea-
sures across different cultures. In this review,
there were no data available on a formal cross-
cultural validation for any of the included mea-
sures when applied to HD populations. Conse-
quently, cross-cultural validation should be
implemented in future development programs of
HRQoL measures in HD.
3. We discussed the need for a generic measure ver-
sus a disease-specific measure. Given the complex-
ity of the clinical presentation of HD, it is likely
that a generic scale will not capture all the disease
features that significantly impact on the HRQoL
of these patients, and thus a disease-specific mea-
sure may be better positioned to capture HRQoL
in HD in a valid manner. On the other hand,
although disease-specific measures are usually
more sensitive, generic measures are able to cap-
ture global aspects of health that may be over-
looked by the specific scales. A disease-specific
measure that incorporates items likely found in
generic measures is possibly the best approach.
The committee also looked at caregiver-centered QoL
measures. We recognize that these measures have their
own issues. In this review, we included 2 caregiver-
centered QoL measures, 1 developed in Alzheimer’s dis-
ease and another specifically developed for HD. Although
caregivers play a role in caring for patients with a wide
range of neurodegenerative disorders, and there are many
features in common between caring for such patients and
caring for a progressively dependent patient, there are
limited data available to determine if similarities across
neurodegenerative disorders are sufficient to warrant a
general QoL scale or whether caregiver QoL needs to be
disease specific. A caregiver-centered measure that con-
siders both disease-specific items and more generic items
would likely be the best approach.
In the current review we identified several measures
that were “listed.” In many cases, these measures have
had limited evaluation of their measurement properties
in HD. Still, other recently developed HD-specific
measures are in the initial stages of comprehensive
measurement property testing, these include the Hun-
tington Disease Health-Related Quality of Life, the
HDQoL, or HD-PRO-TRIAD. Importantly, some of
these newer measures incorporate patient stakeholders
in their development, a contribution deemed essential
by regulatory agencies such as the US Food and Drug
Administration for patient-reported outcomes support-
ing labeling claims.33 Further testing of the measure-
ment properties and uptake of these measures by
groups other than the developers is required to
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determine their real value in evaluating HRQoL in
HD patients. The committee concluded that the evalu-
ation of the measurement properties of the currently
available measures that are included in this review,
namely those developed specifically for HD, is war-
ranted. This should be a priority for HD researchers,
considering for example the increasing importance of
patient-reported outcomes in the development of novel
therapies and their subsequent approval by regulatory
authorities.
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